Von Willebrand factor (VWF) performs two simultaneous jobs inside a damaged blood vessel: it rolls out like a molecular carpet to which platelets can stick, and it ferries coagulation Factor VIII¹¹ coagulation Factor VIII
Factor VIII is the plasma protein deficient in haemophilia A; VWF acts as its stabilizing carrier, protecting it from premature destruction in the bloodstream to the site of injury. Both jobs require VWF's three functional domains — A1 (platelet GpIb binding), A3 (collagen binding), and D (Factor VIII binding) — to work in concert. The rs267607353 variant swaps serine for alanine at residue 1783 of the A3 domain, dismantling just one of these functions: the ability to grip collagen in the vessel wall.

The result is a bleeding disorder that standard coagulation panels routinely miss. Multimers look normal. VWF antigen is normal. The ristocetin cofactor assay (VWF:RCo, which tests platelet-binding) is normal. Only a dedicated collagen-binding assay (VWF:CB) reveals the defect — and most haematology labs do not run it unless specifically requested. This is von Willebrand disease type 2M²² von Willebrand disease type 2M
The "M" stands for "multimer-independent," meaning the collagen-binding defect is not due to loss of high-molecular-weight multimers as in type 2A disease, also described as type 2CB (collagen-binding subtype). Carriers can bleed significantly from dental extractions, surgeries, and childbirth while appearing fully normal on routine haematological workup.

The Mechanism

The VWF A3 domain folds into a von Willebrand A fold³³ von Willebrand A fold
A barrel-like beta-sheet structure common to VWF, integrins, and complement proteins; its surface groove coordinates the collagen interaction that positions a specific surface groove to engage collagen types I and III in the extracellular matrix. Serine 1783 sits within this groove. In the wild-type protein, serine's hydroxyl group contributes a hydrogen bond that maintains the precise geometry of the collagen-contact interface. Substituting alanine — which lacks that hydroxyl side chain — disrupts this geometry without altering the overall multimer structure or Factor VIII binding.

Recombinant S1783A VWF expressed and studied by Riddell et al. showed "a pronounced binding defect to both type I and type III collagen" relative to wild-type, while multimer gels were "indistinguishable from wild-type." This mechanistic specificity — collagen binding lost, everything else preserved — is what makes this variant diagnostically elusive and clinically significant.

The Evidence

The key characterization study is Riddell et al., Blood 2009⁴⁴ Riddell et al., Blood 2009
Riddell AF, Gomez K, Millar CM et al. Blood 114(16):3489-96; doi:10.1182/blood-2008-10-184317 — identified S1783A and W1745C as novel A3-domain mutations in three families with bleeding symptoms and normal routine VWD assays; proposed reclassification of isolated collagen-binding defects as a distinct disease subtype. S1783A was identified as a heterozygous variant in a mother-son pair with bleeding symptoms — normal VWF antigen, normal VWF:RCo, normal multimers, but abnormal collagen binding to both collagen I and III. The variant segregated with the phenotype, and the S1783A mutation was absent from the reference allele population. ClinVar (variation 31012) lists the pathogenic classification from OMIM (allelic variant 613160.0042) along with a 2023 Variantyx submission noting variable expressivity consistent with incomplete penetrance.

The importance of dedicated collagen-binding assays is established by Favaloro and Mohammed, 2014⁵⁵ Favaloro and Mohammed, 2014
Favaloro EJ, Mohammed S. Thromb Res 135(6):1307-16, 2014 — comparative evaluation of VWF assay platforms across 600 samples; VWF:CB was most discrepant from VWF:RCo precisely in type 2M patients, confirming VWF:CB is irreplaceable for this subtype. Without a VWF:CB assay in the diagnostic workup, type 2M/2CB cases are systematically missed.

Evidence level is assessed as strong: the causal mechanism is characterised at the recombinant-protein level, the variant segregates with disease in affected pedigrees, ClinVar lists a pathogenic submission, and the collagen-binding assay literature supports the diagnostic framework. However, published case numbers are small (one pedigree for S1783A specifically) and the full penetrance spectrum is not yet established from population-level data.

Practical Actions

For carriers, the priority is to make the invisible visible: the bleeding risk is real but will remain undetected unless haematologists are told to request a VWF collagen-binding assay. Carriers undergoing surgery, dental procedures, or childbirth need a haematologist involved in pre-procedural planning. DDAVP (desmopressin) — the first-line treatment for VWD type 1 — releases endogenous VWF stores but is unlikely to be effective for this variant because the released VWF carries the same structural defect. VWF concentrate (Humate-P, Wilate, or similar) is the preferred treatment option when haemostatic cover is needed, since concentrate VWF has normal collagen-binding activity.

Interactions

VWF S1783A acts through loss of collagen contact rather than reduction in VWF quantity or multimer structure. It does not interact with the ABO blood group variant (rs505922) in the same way that quantitative VWD type 1 does — ABO-associated VWF level modulation is relevant to VWF antigen and clearance, not to A3-domain collagen binding. No compound heterozygosity has been published for S1783A with other A3-domain mutations (such as W1745C at rs61749642 or L1733P), though theoretically compound heterozygosity could produce severe type 3-like collagen-binding loss; this has not been documented in clinical series.

Estrogen receptor alpha (ERα), encoded by ESR1 on chromosome 6, is the master mediator of estrogen's effects throughout the reproductive system, skeleton, breast, and cardiovascular tissues. ERα regulates the timing of puberty and menopause, drives follicular development in the ovary, governs endometrial proliferation, and controls hypothalamic feedback that synchronizes the HPG axis. Because so much of female reproductive biology runs through this single receptor, polymorphisms that alter how much ERα is made — or how well it responds to estrogen — can shift the timing and quality of reproductive aging in consequential ways.

rs2747648 sits in the 3′ untranslated region (3′UTR) of ESR1, a stretch of the mRNA transcript that does not encode protein but contains regulatory sequences that govern how efficiently the mRNA is translated and how quickly it is degraded. One key class of 3′UTR regulators is microRNAs¹¹ microRNAs
small non-coding RNA molecules, approximately 22 nucleotides long, that bind to complementary sequences in mRNA 3′UTRs and suppress protein production by blocking translation or triggering mRNA degradation.

The Mechanism

The rs2747648 variant creates or disrupts a binding site for miR-453²² miR-453
microRNA-453, a small regulatory RNA expressed in reproductive and breast tissues that targets ESR1 mRNA for translational repression. Computational analysis confirmed experimentally by Tchatchou et al. 2009³³ Tchatchou et al. 2009
Carcinogenesis — familial breast cancer study of miRNA target site SNPs in cancer-related genes showed that the C allele strengthens miR-453 binding affinity, allowing miR-453 to more effectively suppress ESR1 mRNA translation. The result: lower ERα protein levels in cells carrying the C allele.

The T allele (the allele carried by ~97% of people globally) weakens miR-453 binding. ESR1 mRNA is less efficiently repressed, yielding higher baseline ERα protein levels. This is the population-typical state — most people have TT and average ERα expression at this locus.

Higher ERα levels, while normal, are not neutral for all tissue contexts: in breast epithelium, estrogen receptor signaling drives cellular proliferation, and elevated receptor abundance is a recognized driver of estrogen-dependent breast cancer, particularly in premenopausal women when estrogen levels are highest.

The Evidence

The primary evidence for rs2747648 comes from a familial breast cancer study⁴⁴ familial breast cancer study
Tchatchou et al. Carcinogenesis 2009; analysis of 11 miRNA target site SNPs across a large familial cohort that identified significant association with premenopausal breast cancer risk. Women carrying at least one C allele had OR = 0.60 (95% CI 0.41–0.89, p=0.010) for premenopausal breast cancer compared to TT homozygotes — a 40% reduction in relative risk. The protective effect was even stronger in high-risk familial cases (OR = 0.42, 95% CI 0.25–0.71, p=0.0009).

The fertility and reproductive aging implications of this variant are inferred from the broader ESR1 locus literature. Multiple studies have linked ESR1 polymorphisms to premature ovarian failure (POF) and age at natural menopause. Schuh-Huerta et al. 2012⁵⁵ Schuh-Huerta et al. 2012
Orphanet Journal of Rare Diseases — ESR1 variants associated with both age at natural menopause and premature ovarian failure in independent cohorts showed that nearby ESR1 variants (rs2234693) are significantly associated with both age at menopause and POF risk — consistent with a shared genetic architecture across the ESR1 locus. Cordts et al. 2012⁶⁶ Cordts et al. 2012
Journal of Assisted Reproduction and Genetics — ESR1 PvuII polymorphism associated with POF under a recessive model, p=0.034, in Brazilian women with n=70 POF cases and 73 controls and Yang et al. 2010⁷⁷ Yang et al. 2010
Journal of Women's Health — ESR1 XbaI/PvuII haplotypes modify POF risk; X allele OR 0.6 for idiopathic POF in Korean women further confirm ESR1's role in setting the pace of ovarian aging.

The C allele's impact on ESR1 expression in reproductive tissues has not been directly studied in ovarian or endometrial biopsies for this specific variant. The connection to reproductive function is mechanistically plausible (lower ERα in ovarian follicles and hypothalamic neurons could alter folliculogenesis and GnRH feedback) but is classified as emerging evidence for this specific rsid.

Practical Implications

For the rare individuals (approximately 1 in 20) who carry the C allele (CT or CC), the primary implication is a genetically lower risk of premenopausal breast cancer, driven by reduced ERα abundance. For CT heterozygotes — the dominant non-normal genotype — the effect is partial.

The fertility implications of reduced ERα expression are less well characterized for this specific variant. In animal models, loss of ERα function consistently disrupts follicular maturation, ovulation, and hypothalamic GnRH pulsatility. Whether the modest reduction in ERα expected from one C allele at this regulatory site has any measurable effect on ovarian reserve or menopause timing is not established from direct studies of rs2747648. Monitoring reproductive hormone levels (FSH, AMH, estradiol) provides the most actionable pathway if concerns arise.

Interactions

rs2747648 is in physical proximity to several well-studied ESR1 variants, including rs2234693 (PvuII, intron 1)⁸⁸ rs2234693 (PvuII, intron 1)
ESR1 polymorphism associated with endometrial receptivity, bone density, and POF risk in multiple cohorts, rs9340799 (XbaI, intron 1)⁹⁹ rs9340799 (XbaI, intron 1)
ESR1 variant associated with endometriosis-related infertility and IVF failure, and rs1159327 (intron variant, associated with bone mineral density). Haplotype effects across these variants are likely, since they span the regulatory introns that control ERα tissue-specific expression.

The HLA-DPA1 gene¹¹ HLA-DPA1 gene
Human Leukocyte Antigen class II, DP Alpha 1 — encodes the alpha chain of the HLA-DP heterodimer, a surface receptor on antigen-presenting cells that displays peptide fragments to CD4+ T helper cells, initiating adaptive immune responses against pathogens sits at the centre of how your immune system recognises and clears hepatitis B virus (HBV). The rs3077 variant sits in the 3′ untranslated region of this gene — not altering the protein itself, but controlling how much of it gets made. The G allele at this position (equivalent to the C allele on the coding strand in many papers, because HLA-DPA1 is transcribed from the minus strand) silences HLA-DPA1 production in the liver, leaving the immune system less equipped to present HBV antigens and mount a clearing T-cell response.

The Mechanism

HLA-DP molecules are class II major histocompatibility complex²² major histocompatibility complex
MHC — the genomic region on chromosome 6p21 encoding cell-surface proteins that present peptide antigens to immune cells; essential for self/non-self discrimination and adaptive immunity proteins expressed on antigen-presenting cells — dendritic cells, B cells, macrophages, and Kupffer cells in the liver. They display short viral peptides to CD4+ T helper cells, which in turn coordinate antibody production by B cells and activation of CD8+ cytotoxic T cells that kill virus-infected hepatocytes. The rs3077 variant is the single strongest expression quantitative trait locus³³ expression quantitative trait locus
eQTL — a genetic variant that controls the quantity of mRNA produced from a nearby gene; the rs3077 signal for HLA-DPA1 mRNA reached p=10⁻⁴⁸ in a genome-wide scan of liver tissue for HLA-DPA1 mRNA in human liver. Carrying the G allele means liver cells produce less HLA-DPA1 protein — meaning fewer HBV peptides are displayed, CD4+ T-cell help is blunted, and the virus is more likely to establish chronic infection rather than being cleared.

The Evidence

The association between rs3077 and hepatitis B chronicity is one of the most consistently replicated genetic findings in HBV research. A landmark study by An et al. 2011 in 1,742 Han Chinese⁴⁴ An et al. 2011 in 1,742 Han Chinese
A common HLA-DPA1 variant is a major determinant of hepatitis B virus clearance established that the A allele (protective) was associated with a more than doubled likelihood of HBV clearance (OR 2.41, p<0.001) and a 38% reduced risk of chronic infection (OR 0.62, p=0.001). A subsequent meta-analysis of eight studies by Zhang et al. 2013⁵⁵ meta-analysis of eight studies by Zhang et al. 2013
Association of the rs3077 and rs9277535 polymorphisms with HBV infection and spontaneous clearance; pooled analysis of Asian cohorts confirmed an additive dose-response: each copy of the protective A allele further reduces the odds of chronic HBV, with AA homozygotes showing an OR of 0.35 (65% risk reduction) relative to GG homozygotes.

The same signal shapes hepatitis B vaccine response⁶⁶ hepatitis B vaccine response
Standard HBV vaccination induces protective anti-HBs antibody titres ≥10 mIU/mL in >90% of recipients; the G allele at rs3077 is associated with impaired antibody production, making carriers more likely to be non-responders. A Japanese study of 278 healthcare workers found rs3077 was strongly associated with vaccine antibody response (OR 0.32, p=0.010) — GG carriers were disproportionately likely to fail to mount protective anti-HBs titres after standard vaccination. The finding replicated in Caucasian cohorts: Vermehren et al. identified a striking OR of 5.1 (CI 1.9–13.7) for HBV infection risk in European G-allele carriers, confirming the association extends beyond Asian populations.

The G allele frequency varies dramatically by ancestry: only ~17% in Europeans, ~30% in South Asians and Latinos, ~49% in Africans, and ~65% in East Asians — mirroring the global pattern of HBV endemicity and likely reflecting differential historical selection pressure from the virus.

Practical Actions

The clinical relevance of this variant depends on HBV exposure and vaccination status. For unvaccinated GG carriers, routine serology and consideration of enhanced vaccination protocols are the primary actions. For AG carriers, standard vaccination monitoring is appropriate. For those already vaccinated, checking post-vaccination anti-HBs titres is informative given the association with non-response. For those already chronically infected, the A allele at rs3077 predicts better HBsAg seroclearance during antiviral therapy — an important consideration for treatment planning with nucleot(s)ide analogues.

Interactions

The rs3077 signal is part of a broader HLA-DP haplotype. Its partner variant [rs9277535 | HLA-DPB1 3′ UTR — the beta-chain counterpart; commonly studied together with rs3077 as a two-SNP HLA-DP haplotype that additively predicts HBV outcomes], located in HLA-DPB1 (the beta chain gene adjacent to HLA-DPA1), independently tags HBV clearance and vaccine response. The CA haplotype (rs3077 A + rs9277535 A on the coding strand — i.e., plus-strand A at rs3077 + plus-strand A at rs9277535) is more strongly protective than either SNP alone (OR 0.57, CI 0.36–0.92 in the Indonesian replication study). This compound haplotype effect makes a strong case for profiling both variants together when assessing HBV susceptibility.

SIX6 (sine oculis homeobox homolog 6) is a transcription factor¹¹ transcription factor
A protein that binds to specific DNA sequences to control gene expression critical for eye development, particularly the formation of the retina²² retina
The light-sensitive layer at the back of the eye, optic nerve, and pituitary gland during embryonic development. While most people think of developmental genes as only mattering before birth, SIX6 continues to be expressed in the adult retina, where it plays a surprising role in retinal ganglion cell³³ retinal ganglion cell
Neurons that transmit visual information from the eye to the brain health and survival throughout life.

The rs33912345 variant, which changes a single amino acid at position 141 from asparagine (Asn, encoded by A) to histidine (His, encoded by C), is one of the most robustly replicated genetic risk factors⁴⁴ robustly replicated genetic risk factors
Confirmed across multiple independent studies in different populations for primary open-angle glaucoma (POAG), the most common form of glaucoma worldwide and a leading cause of irreversible blindness. About 15% of people of European descent carry two copies of the risk variant (CC), while this climbs to higher frequencies in East Asian populations where POAG is also more prevalent.

The Mechanism

The Asn141His substitution occurs within the homeodomain⁵⁵ homeodomain
A highly conserved DNA-binding region found in many developmental transcription factors, specifically in the alpha helix structure⁶⁶ alpha helix structure
A common protein structural motif that binds to the DNA major groove that makes direct contact with DNA. Remarkably, the protective Asn141 variant appears to be unique to humans—all other species studied carry the His141 version, suggesting the Asn variant may have been selected for during human evolution, possibly as protection against glaucoma.

Zebrafish complementation assays⁷⁷ Zebrafish complementation assays
A laboratory technique where human gene variants are tested in fish embryos to assess their function have demonstrated that the His141 (risk) variant has reduced function compared to Asn141, affecting both eye size and optic nerve volume during development. In adult humans, the mechanism becomes even more intriguing: the His141 variant drives increased expression of P16/INK4A⁸⁸ P16/INK4A
A cell cycle inhibitor protein that prevents cells from dividing, triggering cellular senescence⁹⁹ cellular senescence
A state where cells stop dividing and begin to dysfunction, similar to aging specifically in retinal ganglion cells (RGCs). This premature aging of the neurons that carry visual signals from your eye to your brain makes them more vulnerable to elevated intraocular pressure¹⁰¹⁰ intraocular pressure
The fluid pressure inside the eye, measured in mmHg and other glaucoma-related stressors.

The Evidence

The association between rs33912345 and glaucoma is exceptionally well-documented. A 2019 meta-analysis¹¹¹¹ 2019 meta-analysis
A statistical method that combines results from multiple studies to increase power pooled data from 22 studies involving over 10,500 POAG cases and 16,700 controls, confirming significant associations in both East Asian and Caucasian populations but not in South Asian or African cohorts, highlighting important ancestry-specific effects¹²¹² ancestry-specific effects
Genetic variants that have different impacts in different population groups.

In the EPIC-Norfolk Eye Study¹³¹³ EPIC-Norfolk Eye Study
A large population-based cohort study in the United Kingdom of over 5,400 Europeans, each C (risk) allele was associated with a 0.030 mm² smaller optic disc rim area (P=5.4×10⁻⁹), a 0.025 larger vertical cup-disc ratio¹⁴¹⁴ vertical cup-disc ratio
The ratio of the optic cup (central depression) to the disc; larger ratios indicate nerve damage (P=3.3×10⁻¹⁰), and a 0.39 μm thinner RNFL¹⁵¹⁵ RNFL
Retinal nerve fiber layer, the innermost layer of the retina containing ganglion cell axons (P=0.001). The Singapore Chinese Eye Study¹⁶¹⁶ Singapore Chinese Eye Study
Population study of over 1,200 Chinese individuals, where the C allele frequency reaches 80%, found even more pronounced effects: each C allele reduced RNFL thickness by 1.44 μm (P=0.001), with the strongest impact in the superior and inferior sectors where glaucomatous damage typically begins.

For disease risk, a Chinese population study¹⁷¹⁷ Chinese population study
Case-control study of 866 POAG patients and 266 controls found an odds ratio of 1.49 for POAG overall (P=3.84×10⁻⁴), climbing to 2.27 for normal-tension glaucoma¹⁸¹⁸ normal-tension glaucoma
A form of glaucoma that occurs despite normal eye pressure (P=2.72×10⁻⁶). The age-stratified analysis revealed that the genetic effect was strongest in individuals aged 40 and above, consistent with the adult-onset nature of most glaucoma.

Critically, a 2014 study¹⁹¹⁹ a 2014 study
First to identify the Asn141His variant through targeted sequencing comparing POAG patients who were homozygous for different genotypes found that CC individuals had significantly thinner global RNFL (58.3 ± 8.2 μm) compared to AA individuals (67.9 ± 12.4 μm, P=0.03), suggesting that the variant's structural effects on the optic nerve precede and may predispose to glaucomatous degeneration.

Practical Implications

This variant matters most for glaucoma screening and prevention. If you carry one or two copies of the C allele, you have measurably thinner retinal nerve fiber layers and altered optic disc structure even before any disease develops. This means you're starting with less "neural reserve" in your optic nerve, making you more susceptible to damage from elevated eye pressure, vascular insufficiency, or normal aging.

The good news: glaucoma is detectable and treatable²⁰²⁰ glaucoma is detectable and treatable
Early detection and pressure-lowering treatment can prevent vision loss when caught early. Baseline comprehensive eye exams²¹²¹ comprehensive eye exams
Include tonometry for pressure, ophthalmoscopy for optic nerve, and perimetry for visual fields by age 40 are recommended for everyone, but if you carry C alleles at rs33912345—especially if you have other risk factors like family history²²²² family history
First-degree relatives with glaucoma increase risk 4-9 fold, high myopia, or African ancestry—consider starting screening in your 30s and maintaining more frequent monitoring (annually rather than every 2-3 years).

Intraocular pressure²³²³ Intraocular pressure
Normal range is 10-21 mmHg; elevated pressure is the primary modifiable risk factor is the main modifiable risk factor. If your eye pressure trends toward the higher end of normal (>18 mmHg) and you carry C alleles, discussing preventive strategies with your ophthalmologist is warranted. Beyond pressure, cardiovascular health appears linked²⁴²⁴ cardiovascular health appears linked
Glaucoma shares risk factors with vascular disease including hypertension and atherosclerosis to glaucoma risk through effects on optic nerve blood flow, so maintaining healthy blood pressure, avoiding smoking, and regular aerobic exercise may provide additional protection.

For those already diagnosed with glaucoma, knowing your SIX6 genotype may influence treatment aggressiveness. CC individuals might benefit from tighter target intraocular pressure²⁵²⁵ target intraocular pressure
The pressure level aimed for to prevent progression, typically <15 mmHg in advanced cases goals given their compromised baseline optic nerve structure.

Interactions

The SIX6 locus contains several variants in strong linkage disequilibrium²⁶²⁶ linkage disequilibrium
Genetic variants inherited together more often than expected by chance, particularly rs10483727, which was the original GWAS discovery SNP (r²=0.95-0.98 with rs33912345). The two variants are so closely linked that they likely represent the same functional signal, with rs33912345 being the likely causal variant given its direct effect on protein function.

There is evidence of potential gene-gene interplay²⁷²⁷ gene-gene interplay
SIX6 and CDKN2B-AS1 independently associated with glaucoma subtypes between SIX6 and the CDKN2B-AS1 locus²⁸²⁸ CDKN2B-AS1 locus
Another major POAG risk locus at chromosome 9p21 at 9p21, one of the most replicated glaucoma risk loci. The interaction involves trans-regulation²⁹²⁹ trans-regulation
When a transcription factor at one genomic location controls gene expression at a distant location, with the SIX6 His141 variant affecting expression of CDKN2A and CDKN2B genes, both of which are cell cycle regulators. Individuals carrying risk alleles at both loci may experience synergistic increases in glaucoma susceptibility, though specific compound recommendations await validation in larger interaction studies.

The SIX6-P16/INK4A pathway also shows interaction with TP53³⁰³⁰ TP53
The tumor suppressor gene that regulates cell cycle and apoptosis, with mouse studies demonstrating that absence of either Six6 or P16 protects against retinal ganglion cell death under elevated intraocular pressure conditions, suggesting potential therapeutic targets for future neuroprotective treatments.

Every egg a woman will ever ovulate was set aside before she was born. Between embryonic day 13 and the first weeks of postnatal life, primordial oocytes cluster in [germ cell nests | syncytial cysts where 10–30 oocytes share cytoplasm through intracellular bridges, formed during the proliferative phase of oogonial division] that must be broken apart and individually wrapped in flattened granulosa cells to form the primordial follicles that constitute the ovarian reserve. The efficiency of this assembly process — how many oocytes survive, and how many are culled by apoptosis during nest breakdown — determines the starting size of the follicle pool that a woman draws down across her reproductive lifespan.

HEY2¹¹ HEY2
Hairy/Enhancer-of-split Related with YRPW Motif protein 2; a bHLH transcriptional repressor that serves as a downstream effector of the Notch signaling pathway in developing follicles is one of the key molecules controlling this critical window. rs3734637 is a variant in HEY2's 3'UTR — the regulatory tail end of the mRNA — where it can influence mRNA stability, polyadenylation site selection, or microRNA binding.

The Mechanism

During the neonatal period when follicle assembly occurs, the Notch2 receptor is activated in pregranulosa cells by the Jagged1 ligand expressed on adjacent oocytes. This Notch2 signal drives transcription of HES1 and HEY2²² HES1 and HEY2
two related bHLH repressor proteins; their shared YRPW motif mediates interaction with the NuRD histone deacetylase complex, compacting chromatin at target gene loci to silence them. The downstream effect of this HEY2 activation in pregranulosa cells is non-cell-autonomous control of oocyte apoptosis — precisely calibrating how many oocytes survive nest breakdown versus how many are sacrificed to provide materials for the survivors.

HEY2 exerts its repressive function in part through physical association with SIRT1³³ SIRT1
an NAD+-dependent class III histone deacetylase; the same enzyme activated by NMN/NR supplementation that supports DNA repair in oocytes. Iso et al. 2003 demonstrated that SIRT1 co-immunoprecipitates with HEY2 and participates in its transcriptional repression at Notch target loci — connecting the HEY2-Notch axis to the broader chromatin state circuitry that also governs oocyte DNA integrity.

The G allele at rs3734637 is the GRCh38 reference and represents the baseline HEY2 regulatory state. The T allele is the derived alternate allele, present at approximately 55% globally (rising to ~75% in East Asian populations), and may mark elevated HEY2 mRNA stability or translation efficiency — effectively providing a modest boost to the Notch-HEY2 signal during follicle assembly. This pattern parallels rs9796 in the INO80 3'UTR, where the non-reference T allele is similarly associated with higher expression and better ovarian reserve.

The Evidence

The most direct functional evidence comes from two independent lines:

Trombly et al. 2008⁴⁴ Trombly et al. 2008
Suppression of Notch signaling in the neonatal mouse ovary decreases primordial follicle formation. Endocrinology 150:1014–1024 used gamma-secretase inhibitors to block Notch signaling in neonatal mouse ovaries and measured follicle assembly outcome. Inhibitor-treated ovaries retained 64% of germ cells in nests versus 42% in controls, while primordial follicle formation fell from 58% to 35% — a 40% reduction. Critically, Hey2 mRNA increased 5-fold between postnatal days 0 and 6 in controls, and HEY2 transcript was localized specifically to pregranulosa cells of primordial follicles. Blocking Notch prevented this Hey2 upregulation and impaired follicle assembly.

Xu & Gridley 2013⁵⁵ Xu & Gridley 2013
Notch2 is required in somatic cells for breakdown of ovarian germ-cell nests and formation of primordial follicles. BMC Biology 11:13 established the causal pathway in vivo: female mice with somatic-cell-specific Notch2 deletion showed impaired germ-cell nest breakdown, multi-oocyte follicle formation, and reduced fertility. The mechanism is non-cell-autonomous — HEY2 in pregranulosa cells signals back to regulate oocyte apoptosis, providing a precise mechanism by which variation in HEY2 expression levels could alter the size of the primordial follicle pool established at birth.

The HEY2-SIRT1 physical association (Iso et al. 2003, Biochem Biophys Res Commun 301:250–257, PMID 12535671) places this variant at the intersection of the Notch-follicle-formation axis and the broader NAD+/chromatin remodeling network that governs ovarian aging.

The rs3734637 G allele reached genome-wide significance (p=3×10⁻⁸) for height in the Yengo et al. 2022 GIANT GWAS⁶⁶ Yengo et al. 2022 GIANT GWAS
Ultra-large GWAS of 5+ million individuals; the largest human height study to date, confirming this as a functional regulatory variant in HEY2's 3'UTR with measurable effects on gene expression — though the reproductive biology connection has not yet been tested in a dedicated human GWAS of ovarian reserve or age at natural menopause.

Practical Actions

Since the reproductive biology evidence is from mouse models and the confirmed human GWAS association is to height rather than fertility, actions for GG carriers are monitoring-focused. Follicle pool size is determined before birth, so the relevant biological window cannot be intervened on directly. What can be done is tracking the reserve from a younger baseline to detect any accelerated decline early, and maintaining the NAD+/SIRT1 axis that HEY2 depends on.

Interactions

HEY2 operates downstream of the Notch2-Jagged1 signaling cascade that governs granulosa-oocyte communication during follicle assembly. The most relevant interaction partner in the GeneOps database is rs9796 (INO80) — INO80's role in DNA double-strand break repair during meiotic recombination in oocytes and HEY2's role in controlling the size of the primordial follicle pool represent convergent mechanisms shaping ovarian reserve. Carriers of GG at rs3734637 (baseline HEY2 signaling, no T allele boost) alongside AA at rs9796 (baseline INO80 repair activity) could face compounding disadvantage: a potentially smaller starting follicle pool combined with less efficient repair of the DNA damage that depletes it over time.

rs2277339 (PRIM1) is a second relevant partner: PRIM1 DNA primase efficiency and HEY2 follicle-assembly signaling represent independent pathways both contributing to functional ovarian reserve. Women lacking protective alleles at both loci may have a broader polygenic disadvantage that warrants earlier and more proactive ovarian reserve monitoring.

Every joint in your body is partially sustained by a microscopic scaffolding of blood vessels. In rheumatoid arthritis, that scaffolding becomes a liability: new vessels grow into the synovial membrane¹¹ synovial membrane
The synovium is a thin membrane lining the joint cavity that produces lubricating fluid; in RA it becomes inflamed, thickened, and vascularized, forming the destructive "pannus" tissue that erodes cartilage and bone, feeding the invasion of immune cells and accelerating joint destruction. Integrin alpha-V, encoded by ITGAV on chromosome 2, is one of the key cell-surface receptors that controls this pathological vascular growth. The rs3738919 variant sits within an intron of ITGAV and may subtly alter how much of this receptor is expressed in synovial and immune cells — though the picture remains contested.

ITGAV encodes the alpha-V subunit that pairs with multiple beta partners (β1, β3, β5, β6, β8) to form integrin heterodimers. The best-characterized of these, integrin αvβ3²² integrin αvβ3
Also called the vitronectin receptor; binds RGD motifs in extracellular matrix proteins including fibronectin, vitronectin, and osteopontin; expressed on endothelial cells, osteoclasts, and activated macrophages, is a critical mediator of angiogenesis and is highly expressed on the new blood vessels that supply the RA synovium. Blocking αvβ3 reduces synovial vascular density in animal models, establishing a mechanistic rationale for investigating ITGAV genetic variants in RA.

The Mechanism

rs3738919 is an intronic variant in ITGAV (GRCh38 chr2:186,656,533, C>A substitution) with no direct protein-coding consequence. Located within an intron of the gene, it may function as a regulatory tag³³ regulatory tag
Intronic SNPs in strong linkage disequilibrium with nearby regulatory elements — enhancers, splice signals, transcription factor binding sites — can influence gene expression without altering the protein sequence for a haplotype affecting ITGAV transcriptional activity or mRNA processing in joint-resident or immune cells. No functional studies have directly measured whether the C or A allele at rs3738919 alters ITGAV expression levels in synovial tissue.

The biological rationale is strongest through the integrin αvβ3 angiogenesis axis. During RA, activated synovial fibroblasts and macrophages upregulate ITGAV-containing integrins to enable adhesion to the extracellular matrix, migration, and recruitment of additional inflammatory cells. If rs3738919 tags a variant that increases ITGAV expression, carriers of the C allele might mount a more robust vascular response to synovial inflammation — accelerating the pannus formation that drives joint erosion.

The Evidence

The original signal came from a family-based study⁴⁴ family-based study
Family-based designs use unaffected relatives as genetic controls, eliminating population stratification as a confound — a methodological strength for candidate gene studies in 100 French Caucasian RA trio families, replicated in 265 additional European families. The combined result showed the C allele was over-transmitted to affected offspring: OR 1.94 (95% CI 1.3–2.9, P=0.002). The accompanying editorial noted this finding "supports the role of angiogenesis in rheumatoid arthritis" as a genetically encoded susceptibility mechanism — one of the first family-based studies to implicate an angiogenesis gene in RA.

However, the larger replication effort substantially undermined this conclusion. A meta-analysis of four Caucasian cohorts⁵⁵ meta-analysis of four Caucasian cohorts
740 + 713 RA cases (NZ and Oxford) plus two independent replication cohorts, totaling 3,527 cases and 4,126 controls found no evidence of association (combined OR 0.92, 95% CI 0.80–1.07, P=0.29). A subsequent six-study meta-analysis⁶⁶ six-study meta-analysis
5,794 RA patients and 5,297 controls across studies in multiple ethnic populations confirmed that rs3738919 is not associated with RA risk in the overall population.

Notably, a related ITGAV variant — rs3768777⁷⁷ rs3768777
A different intronic polymorphism in the same gene, which showed OR 2.3 for RA in a Turkish cohort (P<0.0001) and OR 3.51 (P<0.0001) for Caucasians in the 2020 meta-analysis — has shown ethnicity-stratified association that rs3738919 lacks. This suggests rs3768777, not rs3738919, may be the functional or tagging variant at the ITGAV locus with clinical relevance for RA. The two variants may be in partial but imperfect linkage disequilibrium, explaining why initial studies positive for rs3738919 might have been capturing the rs3768777 signal.

Practical Actions

For individuals carrying one or two copies of the C allele at rs3738919, the evidence does not currently support a strong clinical intervention tied specifically to this variant. The contested replication means the C allele's RA risk status must be interpreted cautiously. Monitoring inflammatory biomarkers is reasonable for those with other RA risk factors (first-degree relatives with RA, carriage of shared epitope HLA alleles, positivity for ACPA or rheumatoid factor on clinical testing). The ITGAV-αvβ3 angiogenesis pathway does, however, offer a mechanistic rationale for dietary interventions that modulate synovial vascularity and integrin signaling.

Interactions

The strongest interaction context is the ITGAV locus itself. rs3768777 in the same gene has substantially stronger and better-replicated RA association evidence than rs3738919 and may represent the functionally relevant variant at this locus. Individuals carrying risk alleles at both rs3738919 and rs3768777 may have higher ITGAV-related susceptibility, though no combined study has formally evaluated this pairing. Beyond the ITGAV locus, integrin αvβ3 interacts with inflammatory cytokine pathways — TNF-alpha upregulates αvβ3 expression on synovial endothelium, suggesting that carriage of TNF-alpha pathway risk variants (e.g. rs1800629 in TNF) may compound synovial vascular risk in ITGAV C-allele carriers.

Every molecule of uric acid your body produces eventually reaches the kidney, where it must run a gauntlet of transporters that shuttle it between the blood and the urine. The most important of these is URAT1¹¹ URAT1
Urate Anion Transporter 1, encoded by SLC22A12 — the primary apical exchanger in proximal tubule cells that drives ~90% of renal urate reabsorption. The rs3825016 variant sits inside the SLC22A12 coding sequence at position 258 of the mRNA (NM_144585.4:c.258C>T), causing a synonymous change at codon 86 — the reference CAC (histidine) becomes CAT, still encoding histidine (p.His86=). The protein sequence is identical regardless of genotype, yet the C allele is robustly associated with elevated serum uric acid and hyperuricemia across multiple populations.

This positions rs3825016 as the third member of a natural URAT1 genetic panel: rs505802 (upstream promoter, sets overall URAT1 expression level) and rs121907892 W258X (truncating loss-of-function, causes severe hypouricemia) define the extremes of URAT1 activity, while rs3825016 captures a coding-region signal that operates through a mechanism independent of those two variants.

The Mechanism

Synonymous variants are no longer treated as automatically silent. A synonymous change can alter mRNA secondary structure²² mRNA secondary structure
Changes in local mRNA folding can affect ribosome pausing and translational elongation speed, which in turn affects co-translational protein folding, codon usage³³ codon usage
Certain synonymous codons are read more slowly by the ribosome because the matching tRNA is less abundant — this changes the folding and membrane integration of multi-pass transmembrane proteins like URAT1, or create cryptic splice sites. URAT1 is a twelve-pass transmembrane protein with complex topology; synonymous variation near transmembrane domains 2–3 (where His86 resides) could plausibly influence transporter surface expression or turnover without altering the primary sequence.

Alternatively, rs3825016 may be in linkage disequilibrium with a nearby regulatory or functional variant that is the true causal allele. The SLC22A12 locus harbors several variants in varying LD, including the rs505802 promoter haplotype (r² varies by ethnicity). In Han Chinese populations, rs3825016 and rs475688 are both genotyped as part of URAT1 risk panels, suggesting partial LD and potentially additive effects at the locus level.

The Evidence

Meta-analyses of hyperuricemia and gout: Zou et al. (2018)⁴⁴ Zou et al. (2018)
Zou Y et al. Associations between the SLC22A12 gene and gout susceptibility: a meta-analysis. Clin Exp Rheumatol, 2018 pooled 7 studies (1,216 cases, 1,844 controls) and found the C allele was associated with hyperuricemia in the allelic comparison (OR 1.274, 95% CI 1.101–1.474, p = 0.001). This was confirmed and extended in a larger synthesis by Zheng et al. (2022)⁵⁵ Zheng et al. (2022)
Zheng Q et al. Genetic Association Between SLC22A12 Variants and Susceptibility to Hyperuricemia: A Meta-Analysis. Genet Test Mol Biomarkers, 2022, which pooled 20 studies (4,817 cases, 6,819 controls) and confirmed significant association under allelic and dominant models.

Pharmacogenomics — losartan uricosuric response: Sun et al. (2015)⁶⁶ Sun et al. (2015)
Sun H et al. URAT1 gene polymorphisms influence uricosuric action of losartan in hypertensive patients with hyperuricemia. Pharmacogenomics, 2015 studied 101 hypertensive patients with hyperuricemia and found that the CT mutant genotype was significantly more frequent in patients (32.7%) than healthy controls (18.8%, p = 0.02). Patients with the CT genotype showed a blunted serum uric acid reduction in response to losartan compared with CC carriers, suggesting that rs3825016 influences how effectively URAT1-mediated urate reabsorption responds to this antihypertensive drug's uricosuric action. Wu et al. (2021)⁷⁷ Wu et al. (2021)
Wu L et al. The impact of a URAT1 polymorphism on the losartan treatment of hypertension and hyperuricemia. J Clin Lab Anal, 2021 independently replicated this finding (CT more frequent in patients vs controls: 36.9 vs 21.5%, p = 0.03).

Multi-locus gout prediction: Tu et al. (2018)⁸⁸ Tu et al. (2018)
Tu HP et al. Variants of ALPK1 with ABCG2, SLC2A9, and SLC22A12 increased the positive predictive value for gout. J Hum Genet, 2018 demonstrated that adding rs3825016 CC to a panel of ALPK1, ABCG2, and SLC2A9 risk alleles raised the positive predictive value for gout to 99% (OR 55) in Han Chinese. This highlights the additive contribution of rs3825016 within the urate network even though its individual effect size is modest.

Practical Actions

The CC genotype produces the highest C-allele burden at this locus. For individuals with this genotype — especially those of East Asian or African ancestry where CC is the majority genotype — the URAT1 genetic risk from rs3825016 compounds with contributions from the SLC22A12 promoter (rs505802) and the major urate transport genes SLC2A9 and ABCG2. The practical implication is early urate monitoring before symptoms develop. Dietary purines and fructose add a modifiable layer on top of the genetic baseline.

The losartan pharmacogenomics finding has direct clinical relevance: hypertensive patients with the CT genotype may need a higher dose or different drug to achieve uricosuric benefit — this should be discussed with prescribers.

Interactions

rs505802 (SLC22A12 promoter) and rs121907892 (W258X): These three SLC22A12 variants tag different aspects of URAT1 biology. rs505802 modulates URAT1 expression quantity; rs3825016 is a coding-region signal (possibly affecting transporter folding or in LD with a causal variant); rs121907892 W258X abolishes function entirely. Individuals carrying the rs505802 CC and rs3825016 CC genotypes together have additive URAT1-mediated urate reabsorption risk from two independent loci in the same gene.

SLC2A9 (rs3733591) and ABCG2 (rs2231142): The three major urate handling genes — SLC22A12 (URAT1, apical reabsorption), SLC2A9 (GLUT9, basolateral reabsorption), and ABCG2 (BCRP, apical secretion) — operate at independent points in renal urate handling. Risk alleles at all three loci are additive; the Tu et al. 2018 multi-locus analysis demonstrated that stacking rs3825016 CC onto ABCG2 and SLC2A9 risk genotypes raises gout positive predictive value to near certainty.

ALPK1 (rs11726117): The kinase ALPK1 is a trans-regulator of URAT1 protein expression. Kuo et al. 2017 found that the ALPK1 rs11726117 T allele reduces gout risk partly through its suppression of URAT1 at the rs3825016 and rs475688 loci (OR 0.39 in gout cases). This suggests ALPK1 acts upstream of SLC22A12 transcription; individuals with both risk genotypes at ALPK1 and SLC22A12 may have additive URAT1 activity.

Every heartbeat depends on the right amount of sodium in the blood. The kidneys are the master regulators of that balance, and NEDD4L is one of their most critical molecular gatekeepers. This gene encodes an E3 ubiquitin ligase¹¹ E3 ubiquitin ligase
an enzyme that tags specific proteins for degradation by attaching ubiquitin chains to them. Its primary target in the kidney collecting duct is the epithelial sodium channel (ENaC)²² epithelial sodium channel (ENaC)
the principal channel through which sodium is reclaimed from urine back into the bloodstream. By ubiquitinating ENaC subunits, NEDD4L controls how many active channels are present at the cell surface — and therefore how much sodium the kidney retains.

The rs3865418 variant sits within an intron of NEDD4L and tags a haplotype associated with reduced ubiquitin-ligase efficiency toward ENaC. When NEDD4L activity is diminished, more ENaC channels remain at the kidney tubule surface, sodium reabsorption increases, and blood pressure rises — a mechanism remarkably similar to Liddle's syndrome³³ Liddle's syndrome
a rare monogenic hypertension caused by ENaC PY-motif mutations that prevent NEDD4L binding entirely, but acting through a subtler, common-variant mechanism.

The Mechanism

NEDD4L recognizes ENaC through its WW domains, which bind PY motifs on the β- and γ-ENaC subunits⁴⁴ WW domains, which bind PY motifs on the β- and γ-ENaC subunits
creating a molecular handshake that initiates ubiquitin transfer and channel endocytosis. Once ubiquitinated, ENaC is internalized and degraded, reducing sodium reabsorption. This process is under tight hormonal control: aldosterone and the kinase SGK1 phosphorylate NEDD4L, causing it to bind 14-3-3 proteins⁵⁵ aldosterone and the kinase SGK1 phosphorylate NEDD4L, causing it to bind 14-3-3 proteins
sequestering it away from ENaC and temporarily allowing greater sodium reabsorption in response to volume depletion. The rs3865418 T allele tags a haplotype where baseline NEDD4L-ENaC interaction is less efficient, shifting this equilibrium toward sustained sodium retention even under normal salt intake. NEDD4L also regulates NCC (the distal tubule Na⁺-Cl⁻ cotransporter)⁶⁶ NCC (the distal tubule Na⁺-Cl⁻ cotransporter)
another major renal sodium transporter whose overactivity compounds ENaC-mediated hypertension, and knockout studies confirm that renal NEDD4L loss alone causes salt-sensitive hypertension in animal models.

The Evidence

Direct evidence for rs3865418 in humans comes from several Asian population studies. Wen et al. 2008⁷⁷ Wen et al. 2008
Two polymorphisms in NEDD4L gene and essential hypertension in Chinese Hans. Clin Exp Hypertens 2008 conducted a population-based case-control study in Chinese Han individuals and found that the T allele at rs3865418 was associated with significantly higher diastolic blood pressure under a dominant model (p=0.009). The sex-stratified analysis by Liang et al. 2014⁸⁸ Liang et al. 2014
Gender difference in association of NEDD4L gene variants among southern Han Chinese with essential hypertension. Clin Exp Hypertens 2014 in 1,898 participants found rs3865418 associated with hypertension in men (OR=0.71, p=0.009), revealing a gene-by-sex interaction. A review of NEDD4L in cardiovascular disease by Li et al. 2022⁹⁹ Li et al. 2022
Research progress of Nedd4L in cardiovascular diseases. Cell Death Discovery 2022 further confirmed rs3865418 association with hypertension in American and Greek white populations, suggesting the effect is not limited to Asian cohorts.

In the broader NEDD4L context, a large Korean cohort study of 8,842 individuals¹⁰¹⁰ large Korean cohort study of 8,842 individuals
Jin et al. Kidney Blood Press Res 2010 identified 13 SNPs in SCNN1B, SCNN1G, and NEDD4L genes linked to hypertension in case-control analysis, supporting the entire ENaC-NEDD4L regulatory axis as a polygenic determinant of blood pressure. NEDD4L variants conferring salt sensitivity have also been linked to a hazard ratio for cardiovascular disease of 1.13 (95% CI 1.02–1.25)¹¹¹¹ hazard ratio for cardiovascular disease of 1.13 (95% CI 1.02–1.25)
and coronary event risk of 1.20 in longitudinal analyses, indicating that the blood pressure effect translates into downstream cardiac events.

Practical Implications

The T allele tags impaired sodium channel degradation, making you genetically predisposed to salt-sensitive blood pressure responses. Unlike standard hypertension risk, this variant points specifically to the renal sodium-retention pathway — meaning dietary sodium intake is a particularly potent lever. Carriers of NEDD4L risk variants respond more dramatically to dietary salt restriction¹²¹² Carriers of NEDD4L risk variants respond more dramatically to dietary salt restriction
because their kidneys retain more sodium per unit of intake than average. Practical targets from clinical guidelines for salt-sensitive hypertension: dietary sodium below 1,500 mg/day (vs. the general 2,300 mg/day target) and potassium intake of 4,700 mg/day from food to promote natriuresis. Antihypertensive drug classes that target the aldosterone-ENaC axis — spironolactone, eplerenone (aldosterone antagonists), and amiloride (direct ENaC blocker)¹³¹³ spironolactone, eplerenone (aldosterone antagonists), and amiloride (direct ENaC blocker)
these drugs mechanistically counteract the NEDD4L-ENaC dysregulation at its downstream effector — are particularly rational choices for carriers who develop hypertension.

Interactions

rs3865418 belongs to a haplotype block with rs4149601¹⁴¹⁴ rs4149601
a coding variant in exon 1 of NEDD4L that alters isoform expression and is the most functionally characterized NEDD4L SNP. The two variants are often in linkage disequilibrium but have been studied independently in different populations. The rs4149601 G allele reduces ENaC ubiquitination directly; rs3865418 T appears to tag a related but distinct mechanism affecting isoform balance or regulatory efficiency. Carrying risk alleles at both positions would be expected to compound renal sodium retention, though direct compound-genotype data are limited. Other pathway partners include rs2288774 and rs2288775¹⁵¹⁵ rs2288774 and rs2288775
additional NEDD4L intronic variants associated with hypertension in Kazakh and Chinese populations, as well as ENaC subunit variants in SCNN1B and SCNN1G that lie downstream in the same sodium-reabsorption pathway.

Coagulation factor IX is the gatekeeper of the intrinsic clotting pathway. Synthesised in the liver and secreted into the circulation as an inactive zymogen, it is activated by factor XIa to form the tenase complex¹¹ tenase complex
a membrane-assembled enzyme comprising activated factor IX (FIXa), cofactor VIIIa, calcium, and phospholipid that amplifies factor X activation approximately 50,000-fold. Severe loss-of-function mutations in F9 cause haemophilia B. A far more common story is the intronic variant rs422187 — an intron-embedded single nucleotide change sitting 362 bp upstream of exon 5 in the F9 pre-mRNA, with no direct protein-coding consequence. Its relevance comes entirely from what it tracks: the rs6048 missense haplotype (Factor IX Malmö) and its documented modest protection against deep vein thrombosis.

Because F9 sits on the X chromosome (Xq27.1), males are hemizygous — they carry exactly one allele at rs422187. Genotyping chips typically report hemizygous males as homozygous in raw data, so a male reported as AA carries one A allele and a male reported as CC carries one C allele.

The Mechanism

The rs422187 variant sits at chrX:139550700 (GRCh38), 421 bp from the rs6048 coding variant at position 139551121. Its HGVS transcript designation is c.521-362A>C — 362 nucleotides into the intron preceding coding position 521. VEP classifies the consequence as intron_variant with MODIFIER impact, predicting no direct disruption to splicing signals or protein sequence. There is no curated ClinVar entry for this variant, consistent with its designation as a population-level tag SNP rather than a functional variant in its own right.

The striking feature of rs422187 is its near-perfect linkage disequilibrium with rs6048 in European populations: r²=0.94 in the combined LETS and MEGA cohorts²² r²=0.94 in the combined LETS and MEGA cohorts
Bezemer et al. Haematologica 2009;94(5):693–9, and r²=1.0, D'=1.0 in CEU samples from 1000 Genomes Phase 3. The allele frequencies mirror each other precisely — the C allele of rs422187 (≈30% European) co-segregates with the G allele of rs6048 on the same haplotype. This complete co-inheritance means the two variants are functionally indistinguishable at current resolution: any causal effect attributed to rs6048 could in principle be mediated by rs422187 or any other variant in tight LD.

Bezemer and colleagues investigated 28 nearby variants alongside rs6048 in their primary analysis. rs422187 showed "similarly associated" DVT risk to rs6048 itself, but rs6048 emerged as the single most strongly associated variant — suggesting the missense change (Thr194Ala) may be causal, with rs422187 serving as a correlated intron tag. However, since factor IX antigen levels, activation peptide levels, and endogenous thrombin potential did not differ between genotype groups, the mechanism of protective effect — whether attributed to rs6048 or rs422187 — remains genuinely unknown.

The Evidence

The primary association evidence comes from the Bezemer 2009 LETS + MEGA case-control analysis³³ Bezemer 2009 LETS + MEGA case-control analysis
Irene D Bezemer et al. "F9 Malmö, factor IX and deep vein thrombosis." Haematologica 2009;94(5):693–9. Combined n=1,849 men (LETS n=380, MEGA n=1,469). The analysis specifically tested rs422187 among 28 nearby variants and found it in near-perfect LD with rs6048, with comparable DVT association. The lead signal (rs6048 G allele) carried an odds ratio of 0.80 (95% CI 0.69–0.93) for DVT protection. Because of the near-perfect LD, rs422187 C allele carriers show essentially the same risk shift.

This locus was subsequently confirmed in two large GWAS studies. The Klarin 2019 genome-wide study⁴⁴ Klarin 2019 genome-wide study
Derek Klarin et al. "Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease." Nature Genetics 2019;51:1574–1579. Over 650,000 participants, MVP + UK Biobank identified the F9 locus among 33 genomic loci associated with VTE. The Thibord 2022 cross-ancestry meta-analysis⁵⁵ Thibord 2022 cross-ancestry meta-analysis
Florian Thibord et al. "Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors." Circulation 2022;146:1225–1242. 81,669 VTE cases across 30 studies replicated the F9 signal across European, African, and Hispanic populations, confirming the population-generalisable nature of the protective association.

Recurrence risk was addressed by Roach et al. 2015⁶⁶ Roach et al. 2015
REH Roach et al. "The F9 Malmö sequence variant and sex-related differences in recurrence risk in patients with a first VTE." J Thromb Haemost 2015;13(10):1815–22. Four European cohorts: n=2,185, which found that the Factor IX Malmö haplotype did not explain the observed sex difference in VTE recurrence. The modest protective effect appears to apply primarily to first VTE events.

The effect is modest — OR ~0.80, equivalent to roughly a 20% reduction in first DVT odds. It does not approach the magnitude of Factor V Leiden (OR ~5–7 in heterozygotes) or prothrombin G20210A (OR ~3). The C/G allele of this locus is a tilt, not a shield.

Practical Actions

For carriers of one or two C alleles at rs422187, the practical implications parallel those of rs6048. The modest DVT protection shifts baseline probability slightly downward but does not override other thrombophilic risk factors. Standard DVT prevention measures — particularly during surgery, prolonged immobility, or when taking combined hormonal contraceptives — remain important regardless of this variant's protective direction.

For AA homozygotes (the most common genotype in most populations), no specific action is indicated — this genotype represents population-average factor IX pathway function, and the variant itself is non-coding. Other coagulation variants (Factor V Leiden, prothrombin G20210A) carry much larger effect sizes and are the primary determinants of inherited thrombophilia risk.

The most variable population is African (C allele frequency ~57%) versus East Asian (C allele frequency <1%), meaning the protective allele is substantially more common in populations of African ancestry than in European or East Asian populations.

Interactions

rs422187 and rs6048 are in near-perfect LD and should be treated as marking the same haplotype. If both appear in a genetic profile, they are reporting the same underlying signal. The most clinically relevant interactions are with other coagulation variants: Factor V Leiden (rs6025, OR ~5–7 for heterozygotes) and prothrombin G20210A (rs1799963, OR ~3) are the dominant determinants of inherited thrombophilia risk. The modest protective effect of the F9 C allele would partially offset, but not neutralise, the elevated risk conferred by these stronger variants.

Your heart's arteries are constantly cleared of lipoprotein debris by a network of cell-surface receptors. One of these, LRP8 (also called ApoER2)¹¹ LRP8 (also called ApoER2)
LDL receptor-related protein 8, a member of the LDLR superfamily that binds and internalizes ApoE-containing lipoproteins, does double duty: it clears atherogenic particles from the bloodstream and mediates a protective signaling cascade in platelets. The R952Q missense variant disrupts the cytoplasmic tail of this receptor in a way that amplifies inflammatory signaling and blunts platelet regulation — a combination that has been found repeatedly in families with unusually early heart attacks.

The Mechanism

LRP8 is encoded on the minus strand of chromosome 1 (p32.3). The R952Q substitution — a G→A change in the coding sequence (c.2855G>A), reported as C→T on the genomic plus strand — replaces a positively charged arginine with a neutral glutamine in the intracellular domain of the receptor protein. This region contains signaling docking sites; the amino acid swap alters downstream signal transduction without abolishing receptor expression or ligand binding.

Two distinct mechanisms have been described. First, Shen et al. showed²² Shen et al. showed
Shen GQ et al., Am J Hum Genet 2007 that the Q allele increases activation of [p38 MAPK | p38 mitogen-activated protein kinase, a stress-response kinase that promotes inflammatory gene expression including cytokines and matrix metalloproteinases] when vascular cells are exposed to oxidized LDL. Heightened p38 MAPK activity in arterial wall macrophages and smooth muscle cells accelerates plaque formation and destabilization. Second, LRP8 is expressed on the platelet surface where it mediates ApoE3's inhibitory effect on platelet activation. In mice lacking LRP8, platelet aggregation is dysregulated³³ platelet aggregation is dysregulated
Robertson et al., Thromb Res 2009 — ADP and thrombin trigger excessive aggregation, and in-vivo thrombosis time is prolonged 68–200% depending on allele dose, suggesting a paradoxical platelet hyperreactivity under physiological conditions in humans with impaired LRP8 signaling.

The Evidence

The strongest evidence for R952Q as a cardiovascular risk variant comes from studies specifically enriched for familial and premature disease. In the original discovery cohort of 381 patients with premature CAD/MI versus 560 controls, Shen et al. 2007⁴⁴ Shen et al. 2007 found significant association replicated independently in Italian familial MI cases (248 vs 308 controls) and in the pedigree-based GeneQuest II cohort (441 individuals, 22 families). The association was notably absent in a sporadic, non-familial CAD population, consistent with a variant of moderate penetrance that matters most in a familial context.

A larger haplotype analysis identified a five-SNP risk haplotype TACGC⁵⁵ identified a five-SNP risk haplotype TACGC
Shen et al., Circ Cardiovasc Genet 2014 — containing R952Q as one of its five constituent variants — that was present exclusively in CAD/MI patients and absent in controls across the GeneQuest cohort (P=7.4×10⁻⁷ for CAD; P=2.2×10⁻⁹ for MI), with independent replication in Italian and South Korean cohorts. TACGC homozygotes developed disease earlier and had significantly higher LDL cholesterol than heterozygotes (P<0.05).

The MI risk is further amplified when R952Q co-occurs with the APOE ε4 allele. In 681 Italian subjects (394 MI cases, 287 controls), Martinelli et al. 2009⁶⁶ Martinelli et al. 2009 found that the R952Q QQ/ε4 combination carried an OR of 3.88 (95% CI 1.08–13.9) for MI, more than either variant alone, mediated by progressively lower plasma ApoE concentrations (RR: 0.045, RQ: 0.044, QQ: 0.040 g/L; P=0.047 for trend).

Not all replication attempts succeeded. A large German study including WTCCC data (>6,000 subjects across four European cohorts) found no association⁷⁷ found no association
Lieb et al., J Mol Med 2008. The discrepancy is most plausibly explained by population composition: the positive studies specifically recruited familial early-onset cases, while the negative study included predominantly sporadic disease. R952Q appears to be a moderate-penetrance variant whose effect is most visible in family-enriched cohorts where other shared genetic and environmental risk factors amplify its contribution.

Practical Actions

For T-allele carriers, the most actionable findings center on LDL particle quality (smaller, denser LDL particles are more atherogenic), triglycerides, and thrombotic risk. Monitoring these specific lipid fractions — rather than relying solely on standard total cholesterol — provides the most genotype-relevant picture of cardiovascular risk. The platelet biology findings support particular attention to omega-3 fatty acids, which both reduce platelet reactivity through independent mechanisms and lower triglycerides, addressing two of the pathways disrupted by this variant.

Interactions

The strongest documented interaction is with APOE ε4 (rs429358/rs7412). Carriers of both R952Q (rs5174 TT) and APOE ε4 show the lowest plasma ApoE concentrations and the highest MI odds (OR 3.88), because ApoE is both the ligand cleared by LRP8 and the lipid transport protein whose plasma level is genetically modulated by APOE isoform. When LRP8 receptor function is impaired AND ApoE production or clearance is altered by APOE genotype, the combined dysfunction in lipoprotein clearance is additive.

The TACGC haplotype context (rs7546246, rs2297660, rs3737983, R952Q/rs5174, rs5177) also shows that R952Q does not act entirely alone — it is one node in a multi-SNP haplotype, and the haplotype background partially determines the penetrance of the individual Q allele.